- Report
- January 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- November 2023
- 149 Pages
Global
From €2416EUR$2,499USD£2,075GBP
- Report
- October 2023
- 300 Pages
Global
From €4636EUR$4,795USD£3,982GBP
- Report
- April 2023
- 117 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- August 2022
- 120 Pages
Global
From €4351EUR$4,500USD£3,737GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,201GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,201GBP
- Report
- May 2023
- 160 Pages
Global
From €5800EUR$5,999USD£4,982GBP
- Book
- July 2023
- 1568 Pages
Metoclopramide is a gastrointestinal drug used to treat symptoms of gastroesophageal reflux disease (GERD), diabetic gastroparesis, and nausea and vomiting. It is a dopamine antagonist that works by blocking the action of dopamine in the brain and gastrointestinal tract. It is available in both oral and injectable forms. Metoclopramide is also used to treat symptoms of Parkinson's disease, such as tremor and stiffness.
Metoclopramide is a widely used drug in the gastrointestinal market. It is used to treat a variety of gastrointestinal conditions, including GERD, gastroparesis, and nausea and vomiting. It is also used to treat symptoms of Parkinson's disease.
The market for metoclopramide is highly competitive, with many companies offering generic and branded versions of the drug. Some of the companies in the market include Pfizer, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more
